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WE evaluated the effects of sustained perinatal
inhibition of NO synthase (NOS) on h_peroxia
induced lung injury in newborn rats. N"-nitro-L-
arginine-methyl-ester (L-NAME) or untreated
water was administered to pregnant rats for the
final 7 days of gestation and during lactation;
followed by postnatal exposure to hyperoxia
(>95% 02) or room air. The survival rate of L-
NAME treated pups when placed in >95% 02 at
birth was significantly lower than controls from
day 4 (L-NAME, 87%; control pups, 100%,p < 0.05)
to 14 (L-NAME, 0%; control pups, 53%, p < 0.05).
Foetal pulmonary artery vasoconstriction was
induced by L-NAME with a decrease in internal
diameter from 0.88 + 0.03mm to 0.64 + 0.01mm
in control vs. L-NAME groups (p < 0.05), respec-
tively. We conclude that perinatal NOS inhibition
results in pulmonary artery vasoconstriction and
a decreased tolerance to hyperoxia induced lung
injury in newborn rats.
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Introduction
Nitric oxide produced in the endothelium
plays an important role in regulating vascular
tone by activating soluble guanylate cyclase,
which leads to smooth muscle relaxation through
the synthesis of 8uanosine 3’,5’-cyclic monopho-
sphate (cGMP). The pulmonary circulation’s
release and response to NO,2’3 has been shown
to result in potent pulmonary vasodilator in
foetal lambs. It also modulates pulmonary vas-
cular tone during the early neonatal period.
2 NO
has been recognized as a contributor to the
decrease in pulmonary artery pressure that is
crucial for a neonate’s successful transition from
an intrauterine to an extrauterine environment.
4
In addition to its role in the foetal and transi-
tional neonatal circulation, it has also been
shown to improve systemic arterial oxygenation
in adults with lung injury.
5 Inhibition of endo-
genous NO formation or release decreases the
production of NO by the intact lung and enhan-
ces hypoxic pulmonary vasoconstriction.
6 NO
appears to play a major role in vascular tone
during foetal, transitional and neonatal develop-
ment.
Hyperoxia upsets the normal cellular oxidant-
antioxidant defence equilibrium by producin
marked increases in 02 free radical production.
This process ultimately results in endothelial cell
(C) 1995 Rapid Science Publishers
injury and a hypoxic state] Most studies with
inhibitors of NOS are acute studies as opposed
to sustained chronic administration of NOS inhi-
bitors. In the present study we explored the
ability of the newborn rat to withstand a hyper-
oxic challenge and its associated endothelial cell
injury following chronic perinatal inhibition of
NOS with L-NAME, as well as foetal pulmonary
artery structure and development. We hypothe-
sized that the stress of hyperoxia to the pulmon-
ary endothelium combined with chronic
inhibition of NOS with L-NAME would have dele-
terious effects on the developing neonatal rat.
Materials and Methods
Animals and treatment.. Timed-pregnant rats
(Holtzman, Harlan Sprague-Dawley, Indianapo-
lis) were obtained on the 13th day of a 22-day
gestation (Fig. 1). Following a day of acclimatiza-
tion the dams were randomly assigned to one of
two treatment groups, either a control group or
a L-NAME treatment group. In a rat the 14th day
of gestation represents the beginning of the last
third of pregnancy. We chose to begin NO
blockade at this time since in previous work
8-1
we have demonstrated consistent foetal effects
with NO blockade during the last third of
pregnancy. L-NAME (Sigma Chemical Co., St.
Louis, MO), was administered in the drinking
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FIG. 1. Prenatal and postnatal treatment scheme. Dams in Group
A received L-NAME (l.0mg/ml) prenatally throughout the last
third of pregnancy (beginning on the 13th day of a 22 day
gestation) and throughout the post-natal treatment period (14
days), in drinking water. Following delivery by normal parturition
the pups from equivalently treated (L-NAME and control), newly
delivered litters were randomly assigned to either a hyperoxia
exposure (> 95% 02) or room air exposure group.
water, 1 mg/ml, which was made up fresh dailyl
The control group received drinking water alone.
With little variability, both L-NAME and control
dams consumed approximately 70ml water per
day. This amount calculates to a dose of
180mg/kg/day. The dose range used in this
study, encompassed doses known to reduce the
elevated nitric oxide production associated with
experimental inflammatory bowel disease,’2
and many reports evaluating hypertension
induced by chronic reductions of NOS.12-14 The
oral route of administration has been routinely
used by us and others’4 and is a simple and
reliable approach to the chronic administrations
of NOS inhibitors.
Newborn rats were obtained by normal par-
turition within 6-12 h of delivery of the first pup.
The newborn pups from several equivalently
treated litters (L-NAME or control)were first
pooled and then randomly redistributed to the
equivalently treated, newly delivered darns. Dams
plus ten to twelve pups/litter were randomly
assigned to either a hyperoxic exposure (> 95%
02) or room air exposure group.
Exposures to hyperoxia (96-98%) were con-
ducted in 3.5-cubic-foot clear plastic exposure
chambers. The chambers were opened daily
(10-15 min) to provide fresh food and water, to
weigh the rat litters and to interchange mothers
between litters exposed to 02 and room air, to
avoid O2 toxicity in the nursing dams. The off-
spring were either maintained in hyperoxia or
room air for 14 days for survival studies, or killed
with an overdose of ketamine-xylazine anaes-
thesia after 5 days of either hyperoxia (> 95%
O2) or room air exposure, for the lung analyses
described below. All treatment and surgical pro-
tocols were approved by the Institutional Animal
Care and Use Committee of the Louisiana State
University Center in New Orleans, in accordance
with guidelines of the Declaration of Helsinki and
the National Institutes of Health. Rats were
housed in a facility accredited by the American
Association for Accreditation of Laboratory
Animal Care.
Lung analysis: For the analysis of lung anti-
oxidant enzyme (AOE) activity after 5 days of
>95% 02 or room air exposure, newborn pups
from each group were sacrificed following an
overdose of ketamine-xylazine anaesthesia, and
their lungs were immediately perfused in situ
with ice-cold saline and then homogenized in
cold saline (20-30:1; v/w). Two to three lungs
were pooled per sample to provide adequate
lung tissue for the assays. The homogenates were
frozen at -70C for subsequent AOE analyses.
The activities of total superoxide dismutase,
5
catalase, and glutathione peroxidase
iv were
assayed by standard spectrophotometric techni-
ques. Purified enzyme standards (superoxide dis-
mutase and catalase) were obtained from Sigma
Chemical, and glutathione peroxidase standard
was obtained from Boehringer-Mannheim Co.
(Indianapolis, IN). Lung protein was determined
with purified bovine albumin (Sigma) as a stan-
dard according to the method of Schacterle,
1
and lung DNA was determined with purified calf
thymus DNA (Sigma) as a standard according to
the method of Richards.19
Histological evaluation: Microscopic studies were
carded out to evaluate lung structure. For micro-
scopic studies lungs were inflated in situ through
a tracheal catheter at a constant 20cm H20 pres-
sure (fixative, 10% buffered formalin). Fixation
was continued at room temperature for 48h
before sectioning. From all lungs, similarly orien-
ted sections from similar portions of the left lung
were stained with haematoxylin and eosin.
Pulmonary oedema was microscopically asses-
sed in coded lung sections from evidence of
interstitial or peribronchial-perivascular swelling
and eosinophilic-positive staining (proteinac-
eous) material within the air spaces (intra-alveo-
lar oedema). Pulmonary oedema was also
assessed by comparative wet/dry lung weight
ratios using non-perfused lung lobes weighed
before and after drying in an 80C oven for 48 h
to reach constant weight.
Foetal pulmonary artery diameter: In a sub-
group of L-NAME and control animals, at gesta-
tional day 21, dams were anaesthetized, foetuses
removed by hysterotomy and rapidly frozen in
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Table 1. Comparative parameters in L-NAME and control rats offspring following 5 days in > 95% 02 or room air*
Treatment Body wt Lung wt Lung wt/body wt Protein DNA
group (g) (g) (%) (mg/g lung) (mg/g lung)
Protein/DNA
Air control 13.82 _+ 0.45 0.225 -t- 0.006 1.67 _+ 0.04 153.41 -t- 1.94 8.07 + 0.29 19.25 ___
0.85
Air L-NAME 10.38 -t- 0.49 0.208 -I- 0.017 1.93 _-/- 0.09 151.89 -t- 2.75 7.78 + 0.47 20.05.___ 0.98
02 control 12.67 -I- 0.56 0.198 -t- 0.012 1.53 ___
0.10 152.92 + 3.19 6.22 +__ 0.43* 25.20 + 1.58’
02 L-NAME 9.19 __+ 0.30 0.154 + 0.007 1.66 0.05 149.08 -t-_ 2.01 6.71 + 0.50 23.37 + 1.78
*Values are mean + S.D. for six to eight litters per group.
tStatistically significant with p < 0.05 for air L-NAME vs. air control.
Statistically significant with p < 0.05 for 02 L-NAME vs. 02 control.
tStatistically significant with p < 0.05 for 02 control vs. air control.
Statistically significant with p < 0.05 for 02 L-NAME vs. air L-NAME.
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FIG. 2. Survival of L-NAME-treated and control newborns in
>95% 02 for 14 days (n/n number alive/number placed in
02). The L-NAME treated pup survival rate is significantly
decreased compared with 02 controls at all time periods from 4
to 14 days in hyperoxia. *p < 0.05, Chi-square test.
isopentane chilled with liquid nitrogen
( < 150C). Cryostat sections 10m thick were
mounted and stained on microscopic slides. As
described previously
2 an imagery computer
program was then used to reconstruct the pul-
monary artery using 3D imaging techniques. This
computer mchnology allows measurements of
the internal diameters of the pulmonary arteries
with electronic calipers.
Statistical analysis: Survival rates of the treated
vs. untreated rat pups and assessment of intra-
alveolar edema were compared by Chi-square
testing.
2 For comparing biochemical values for
the two hyperoxic groups with those of the two
air control groups, one-way analysis of variance
was done, followed by Duncan’s multiple range
test.
21 For foetal pulmonary artery diameters,
one-way analysis of variance was done followed
by the Student-Newman-Keuls test. For all sta-
tistical tests, a p < 0.05 value was considered to
represent a significant difference between the
compared values.
Results
Physical characteristics.. The influence of prenatal
L-NAME on pup body weight was determined at
birth, and postnatal L-NAME influence was deter-
mined after 5 days in air and hyperoxia. Body
weights were significantly decreased at birth in
the L-NAME treated offspring (6.08 + 0.40) com-
pared with control offspring (7.45 + 0.10,
p < 0.05). (In previous reports we have addres-
sed the intrauterine foetal growth retardation
associated with prenatal L-NAME administrationS).
Consistent with the reduction in pup size is a
time dependent reduction in placental weight.
We have speculated that inhibition of endothelial-
derived NO may compromise placental function
limiting the maternal-foetal exchange of oxygen,
nutrients and metabolic wastes.
The pups exposed to L-NAME had weights
which remained significantly decreased after 5
days in air (-25%) or in hyperoxia (-27%)
(Table 1) (p < 0.05). Lung wet weights were also
significantly decreased after 5 days in hyperoxia
in the L-NAME (--23%) treated offspring, but this
was in proportion to the reduction in body
weight, as the ratio of lung weight to body
weight was unaltered (Table 1). L-NAME treat-
ment followed by 5 days in air or hyperoxia did
not result in significant changes in the normal
rate of increase of lung protein or DNA content
associated with the neonatal maturation process.
No differences were noted in the protein/DNA
ratio with L-NAME administration although there
was a tendency for this ratio to increase with
hyperoxia (Table 1).
Survival data: The offspring perinatally treated
with L-NAME demonstrated a significantly
decreased survival rate compared to the control
offspring from the 4th day onward in hyperoxia,
with the comparative 13 day survival rate being
> 20 times less (2.3%) for the O2 L-NAME group
vs. the O2 control group (53%) (Fig. 2). The sur-
vival rates for the room air L-NAME and control
groups were 96% and 100%, respectively.
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FIG. 3. Pulmonary artery internal diameters for L-NAME and
control pups, n 7. The L-NAME treated pups had a significant
decrease in pulmonary diameter compared with 02 control.
*p < 0.05, Student-Newman-Keuls test.
Table 2. Comparative pulmonary antioxidant enzyme activities in
L-NAME and control offspring after 5 days in >95% 02 room
air*
Treatment SOD CAT GP
group
Air control 106.4 -t- 4.5 127.9 -t-_ 7.5 0.591 _-t- 0.103
Air L-NAME 101.9 ___
2.0 149.3 6.4 0.713 -t- 0.026
02 control 123.1 -I- 7.5 261.3 -t- 24.1 1.066 _-_+ 0.046
02 L-NAME 112.4 -t- 2.4 296.6 -I- 23.8 1.218 _+ 0.0473
*Values are means ___
S.D. for six to eight litters, 14 to 15 samples per
group. Antioxidant enzymes: superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GP) are expressed as activity units/mg DNA.
Statistically significant with p < 0.05 for 02 L-NAME vs. 02 control.
tStatistically significant with p < 0.05 for 02 control vs. air control,
’llStatistically significant with p < 005 for 02 L-NAME vs. air L-NAME.
Pulmonary artery diameter: Pulmonary artery
internal diameters were significantly reduced in L-
NAME treated vs. control foetuses at 21 days of
gestation (Fig. 3).
Lung biochemistry.. Comparative pulmonary AOE
activity responses after 5 days of hyperoxia were
similar between the O2-L-NAME vs. O2-control
groups (Table 2). Following a hyperoxic chal-
lenge both L-NAME and control groups demon-
strated a significant increase in CAT (99% and
104%, respectively) and GP (71% and 80%,
respectively) following hyperoxic challenge
(Table 2).
Histological studies: Qualitative examination
revealed that all the O2-exposed pups (from
both L-NAME and control groups) had evidence
of perivascular or peribronchiolar oedema
present after 5 days of hyperoxic exposure. This
microscopic finding was further substantiated by
the increased wet/dry lung weights of the O2-
exposed offspring vs. the offspring maintained in
room air from both groups. After 5 days in
hyperoxia, no differences were observed in wet/
dry weights between the L-NAME (5.95 __+ 0.54)
and the control (6.08 4-0.48) offspring (average
air control 5.51-+_0.06). L-NAME did not
appear to alter the dysmorphology associated
with sustained hyperoxia (atelectasis, edema).
Discussion
Mechanisms that regulate vascular tone, growth
and function in the developing pulmonary circu,
lation are incompletely understood.
22 Acetylcho-
line, which putatively causes vascular relaxation
through the release of endogenous NO,
23 is a
potent pulmonary vasodilator in the foetal lamb.
Following birth, it appears that endogenous NO
continues to be a key nodulator of pulmonary
vascular tone in the lamb.
24 Recent studies have
demonstrated that the reduction of pulmonary
vascular resistance after the onset of air breath-
ing is partly caused by the release of NO from
the endothelium.25 Located between the circula-
tion and underlying, smooth muscle, the endothe-
lial cell plays a central role in producing changes
in its physical, chemical and neurohumoral envir-
onment through the production and release of
vasodilators and vasoconstrictors. At birth, the
release of NO appears to be triggered by an
increase in pulmonary oxygen tension, blood
flow and mechanical stretch of the lung.
25 Inhibi-
tion of endogenous NO formation or release
attenuates the reduction of pulmonary vascular
resistance and the elevation in pulmonary artery
blood flow associated with the initiation of air
breathing by the lamb.
6 In rats we have pre-
viously reported a significantly higher basal NO
release in newborn femoral vessels vs. adult
femoral vessels,9 suggesting that up-regulation of
basal NO release is increased throughout the sys-
temic circulation of the newborn compared to
the adult.
Beyond its role in the prenatal and transitional
circulation, NO also modulates pulmonary vas,
2 24 cular tone during the early neonatal period.’ In
a previous report we have also shown an
increase in systemic vascular resistance, measured
by carotid artery cannulation in 21-day old rat
pups following chronic perinatal L-NAME expo-
sure. Blockade of NO has been shown to
augment smooth muscle proliferation and the
release of vasoactive agents in isolated vascular
10 arteries and cell culture systems.
Hyperoxia upsets the normal cellular oxidant-
antioxidant defence equilibrium by producin8
marked increases in 02 free radical production..
This process results in endothelial cell injury and
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a hypoxic state. We explored the ability of
newborn rats to withstand a hyperoxic challenge
following chronic perinatal administration of the
NOS inhibitor, >NAME. We hypothesized that the
stress of hyperoxia to the developing newborn
pulmonary endothelium combined with chronic
perinatal inhibition of NOS would not be well
tolerated. As we anticipated the offspring treated
perinatally with L-NAME demonstrated a sig-
nificantly decreased survival rate compared to the
control offspring from the 4th day onward in
hyperoxia, with the comparative 13 day survival
rate being > 20 times less for the O2-L-NAME
group versus the O2-control group (Fig. 1).
Thus, we have demonstrated possible pulmonary
deleterious effects of perinatal NOS inhibition in
the rapidly growing neonatal lung exposed to
hyperoxia.
The superior ability of newborn infants to
resist O2-induced lung damage (and lethality)
compared with adult animals is at least partly
related to the newborn’s ability to increase its
basal AOE activity levels in response to hyper-
oxia, a biochemical response adult animals do
not demonstr.ate.
26-29 We evaluated whether
perinatal NOS inhibition would negate a neona-
te’s ability to mount a protective AOE response
to a hyperoxic challenge. Our comparative AOE
levels at 5 days of life were not different between
the L-NAME and control pups exposed to hyper-
oxia (Table 2). Hence, chronic perinatal inhibi-
tion of NOS does not alter the neonatal rat’s
ability to mount an AOE response to a hyperoxic
challenge and does not account for the hyper-
oxic lethality in this study. Also, we were not able
to find significant differences in other measures
of O2 radical-induced lung injury, including lung
weight/body weight ratio, DNA or protein
content or protein/DNA ratio in lung tissue
(Table 1), pulmonary oedema (microscopically
or by wet/dry weights) or microscopic evidence
of tissue destruction.
However, near term (21st day of a 22 day
gestation), the internal diameters of pulmonary
arteries from t-NAME treated foetuses were sig-
nificantly smaller than those in control foetuses
(Fig. 2). The distinct mortality data suggests that
t-NAME treatment may have sensitized newborn
rats to the lethal effects of hyperoxia via its
effects on the pulmonary vasculature. Pulmonary
vasoconstriction per se (L-NAME treated neonatal
rats exposed to air) did not cause lethality. Our
findings are in agreement with the work of Kour-
embanas et al., who report that inhibition of NO
augments smooth muscle proliferation and the
release of vasoactive agents in isolated vascular
arteries and cell culture systems.
3 The neonatal
pulmonary circulation can rapidly undergo struc-
tural remodelling, leading to altered vessel dia-
meter and compliance resulting from smooth
muscle cell proliferation. Our current and pre-
vious works merge with the Kourembanas
studies and suggest that inhibition of NO may
alter pulmonary vascular tone and structure.
These changes may result from a decreased
release of vasodilator substances, an increased
release of vasoconstrictors, and an altered
smooth muscle cell responsiveness to vasoactive
mediators, or by structural remodelling of the
pulmonary vessels.
In summary, basal NO release from endothelial
cells is increased throughout the systemic circula-
tion of the newborn compared to the adult9 and
is a key modulator of pulmonary vascular tone
during the transition from foetus to newborn
24
and during the early newborn period.2’24 NOS
inhibition decreases the internal diameter of the
pulmonary, arteries, increases pulmonary vascular
resistance and decreases pulmonary artery
blood flow.
6 The summation of these pulmonary
changes, compounded by hyperoxia induced
endothelial cell injury, significantly alters NO pro-
duction and release to the extent that mortality is
significantly influenced. Further study into the
ontogeny of the t-arginine:NO pathway will
improve our understanding of how the transition
from foetus to neonate is executed, neonatal
development, and potentially target strategies for
remedying damage induced to a developing
neonate from a hyperoxic exposure (i.e. bron-
chopulmonary disease and retinopathy of pre-
maturity).
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